Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

OBJECTIVE Assess safety and efficacy of 10-mg prolonged-release alfuzosin (Xatral XL) in benign prostatic hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS). MATERIAL AND METHOD A multicenter observational study looking at safety by adverse events (AEs) incidence, efficacy by changes in International Prostate Symptom Score (I-PSS), quality of life index (QOL), sexual function using Danish Prostate Symptom Score (DAN-PSS sex), and flow rates. Patients were allocated to receive alfuzosin (Xatral XL) 10 mg once daily tablet along with a meal for 6 months. Patients were assessed at 3 months and 6 months. RESULTS In 118 males, 22% had AEs (most common was dizziness). Ten patients discontinued the treatment. Of those patients, five had serious AEs, which only one was related to the study. At month 6, there were improvements from baseline in mean I-PSS (-9.3, p < 0.001), in QOL index (-2.96, p < 0.001), in symptom (-0.72, p < 0.05) and bothersome (-1.13, p < 0.01) subscores on DAN-PSS sex, and in mean flow rate (0.92, p < 0.01). Approximately 74% patients improved within two weeks. There was one case of Acute urinary retention (AUR), which none required surgery. CONCLUSION A 10-mg prolonged-release alfuzosin safely and rapidly relieves LUTS and maintains improvement. It also improves BPH-associated sexual dysfunction.

[1]  C. Roehrborn.  Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. , 2007, BJU international.

[2]  M. Elhilali,et al.  The beneficial effect of alfuzosin 10 mg once daily in ‘real‐life’ practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation , 2006, BJU international.

[3]  L. Kuritzky,et al.  Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia , 2006, International journal of clinical practice.

[4]  M. Elhilali,et al.  Long‐term efficacy and safety of alfuzosin 10 mg once daily: a 2‐year experience in ‘real‐life’ practice , 2006, BJU international.

[5]  T. Wilt,et al.  Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. , 2005, Urology.

[6]  F. Saad,et al.  Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. , 2005, The Canadian journal of urology.

[7]  C. Roehrborn,et al.  Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. , 2005, Urology.

[8]  C. Roehrborn,et al.  Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies , 2003 .

[9]  AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. , 2003, Journal of Urology.

[10]  C. Roehrborn,et al.  Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. , 2001, Urology.

[11]  N. Oakley.  Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. , 2000 .

[12]  P. V. van Kerrebroeck,et al.  Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. , 2000, European urology.

[13]  F. Debruyne,et al.  Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia , 1998, European Urology.

[14]  D. Comet,et al.  Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice , 1998, Prostate Cancer and Prostatic Diseases.

[15]  S. Roth,et al.  Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. , 1997, European urology.

[16]  A. Leplège,et al.  Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. , 1996, Urology.

[17]  D. Martin,et al.  Effects of alfuzosin on urethral and blood pressures in conscious male rats. , 1995, Life sciences.

[18]  J H Wasson,et al.  A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. , 1995, The New England journal of medicine.

[19]  H. Bensadoun,et al.  Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey , 1994 .

[20]  H. Mensink,et al.  ALFUZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - EFFECTS ON SYMPTOM SCORES, URINARY FLOW-RATES AND RESIDUAL VOLUME - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL , 1994 .

[21]  H. Bensadoun,et al.  Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. , 1994, British journal of urology.

[22]  H. Mensink,et al.  Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. , 1994, Scandinavian journal of urology and nephrology. Supplementum.

[23]  H. Bensadoun,et al.  Long‐term Treatment of Benign Prostatic Hyperplasia with Alfuzosin: a 12–18 Month Assessment , 1993 .

[24]  W. Garraway,et al.  Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. , 1993, The British journal of general practice : the journal of the Royal College of General Practitioners.

[25]  P. Manoury,et al.  Alfuzosin, a selective α1‐adrenoceptor antagonist in the lower urinary tract , 1993 .

[26]  H. Bensadoun,et al.  Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. , 1993, British journal of urology.

[27]  H. Schoemaker,et al.  Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. , 1993, British journal of pharmacology.

[28]  P. Teillac,et al.  Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group. , 1992, British journal of urology.

[29]  H. Bensadoun,et al.  Alfuzosin for treatment of benign prostatic hypertrophy , 1991, The Lancet.

[30]  H. Bensadoun,et al.  Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. , 1991, Lancet.

[31]  M. Barry.  Epidemiology and natural history of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.

[32]  M. Caine.  The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. , 1986, The Journal of urology.

[33]  S. Raz,et al.  Pharmacological receptors in the prostate. , 1973, British journal of urology.